Varex Imaging Corp (VREX) valuation
Varex Imaging P/E ratio history
Varex Imaging trades at 35.4 times its earnings over the last twelve months and 18.2 times the earnings analysts expect over the next twelve. At its last 6 fiscal year ends its P/E ranged from 17.6 (year to Sep 2023) to 70.7 (year to Sep 2019), with a median of 34.4.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Oct 3, 2025 | $11.94 | -$1.70 | n/m | 15.6 |
| Sep 27, 2024 | $11.92 | -$1.20 | n/m | 22.0 |
| Sep 29, 2023 | $18.79 | $1.07 | 17.6 | 15.4 |
| Sep 30, 2022 | $21.14 | $0.73 | 29.0 | 14.4 |
| Oct 1, 2021 | $28.58 | $0.43 | 66.5 | — |
| Oct 2, 2020 | $12.37 | -$1.49 | n/m | — |
| Sep 27, 2019 | $28.28 | $0.40 | 70.7 | — |
| Sep 28, 2018 | $28.66 | $0.72 | 39.8 | — |
| Sep 29, 2017 | $33.84 | $1.36 | 24.9 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Varex Imaging valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Varex ImagingVREX | $776M | 35.4 | 18.2 | 0.9 |
| Collegium PharmaceuticalCOLL | $772M | 19.2 | 3.2 | 1.0 |
| PhreesiaPHR | $769M | 69.1 | 8.7 | 1.5 |
| AdapthealthAHCO | $790M | — | — | 0.2 |
| Cytek BiosciencesCTKB | $792M | — | — | 3.8 |
| Beta BionicsBBNX | $754M | — | — | 5.9 |
| ArdelyxARDX | $748M | — | — | 1.7 |
| OrthopediatricsKIDS | $806M | — | — | 3.1 |
| Pacific Biosciences Of CaliforniaPACB | $809M | — | — | 5.1 |
| Peer median | 44.2 | 6.0 | 2.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: VREX financials · VREX returns
No forecast, no recommendation. This page describes Varex Imaging Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.